Seer Introduces Groundbreaking Proteomic Discoveries at HUPO 2024
Seer, Inc. (Nasdaq: SEER), a dynamic force in life sciences and proteomics, is setting a benchmark in scientific innovation with its presentations at the 23rd Human Proteome Organization (HUPO) World Congress. The congress, hosted in Dresden, Germany, serves as a prestigious platform to unveil major advancements in the field of proteomics. As a dedicated sponsor, Seer demonstrates how its Proteograph™ Product Suite is revolutionizing proteomic research, allowing for unprecedented scalability and efficiency.
Transformative Technologies Driving Proteomic Analysis
The core technologies developed by Seer redefine the approach to proteomic analysis. By automating several key processes, these innovations compress the dynamic range of the proteome, thus empowering researchers to gain valuable insights into human health challenges and diseases. The capability of Seer's solutions goes beyond traditional methods, significantly contributing to personalized medicine, biomarker discovery, and enhancing population health studies.
Omid Farokhzad, CEO and Chair of Seer, emphasizes the impact of their offerings: "The advanced research we present showcases the Proteograph Product Suite’s potential to deliver deep, unbiased proteomic data swiftly and at a scale that was previously impossible. We stand at the forefront of innovation, providing researchers with vital tools to explore complex biological systems at a molecular level, accelerating breakthroughs in precision medicine."
Insights into Alzheimer’s Disease at HUPO 2024
Alzheimer’s Disease: Uncovering Genetic Influences via Proteogenomics
Presented by Harendra Guturu, the study titled Understanding the Impact of Genetic Variants on Alzheimer's Disease with Mass Spectrometry Proteogenomics seeks to analyze nearly 1,800 plasma samples from 1,005 participants. Utilizing Seer’s Proteograph XT, the research investigates the relationship between genetic variants and changes in the proteome concerning Alzheimer’s Disease. This comprehensive analysis yielded 138 differentially abundant protein groups, highlighting potential causal pathways related to the disease's progression.
Advancements in Population Health Proteomics
Population Health Studies: Advances in Large-Scale Plasma Proteomics
Continuing the trend of ground-breaking studies, Lee Cantrell's presentation focuses on achieving remarkable speeds and depths in plasma proteomics. The study, Empowering Robust Population-Scale MS Plasma Proteomics Studies with Nanoparticle Enrichment, tracks a study conducted on 1,600 plasma samples. The introduction of nanoparticle enrichment and plate-based automated preparation allows for identifying over 8,100 proteins, exceeding conventional limits and enhancing the throughput of sample processing.
Innovations in Blood Sampling Techniques
Whole Blood Microsampling: Novel Approaches to Biomarker Studies
Seer’s research expands the applicability of proteomic analysis using dried blood spots (DBS), as presented by Maik Pruess in the session titled Advancements in Nanoparticle-Based Proteomic Analysis of Whole Blood Obtained from Various Dried Blood Spot Collection Devices. By enhancing detection capabilities from approximately 1,000 to up to 3,000 proteins, this method illustrates how DBS coupled with nanoparticle enrichment can lead to significant breakthroughs in early biomarker discovery.
Xenotransplantation Insights from Deep Profiling
Xenotransplantation: Immune Dynamics from Ultra-Deep Profiling
In an innovative study led by Alexey Stukalov, the focus shifts to xenotransplantation. The presentation titled Ultra-Deep Longitudinal Profiling of Plasma and Serum Proteome Provides Critical Insights into the Interaction of Human Organism and Pig Xenotransplants examines the immune responses of patients receiving genetically modified pig organs. Through Seer’s Proteograph XT and advanced LC-MS workflows, researchers conducted a detailed profiling over 61 days, gathering essential data about immune systems that can shape future transplant strategies.
Highlights from Collaborating Institutions at HUPO 2024
Seer’s impact is also seen in collaborations with respected institutions presenting their findings at HUPO 2024, displaying the versatility of the Proteograph platform across a variety of proteomic studies. Researchers from universities and organizations worldwide harness this technology for an array of clinical and discovery proteomics applications, which ultimately enhances sensitivity, scalability, and the depth of analysis.
About Seer
Seer continues to propel advancements in life sciences through its Proteograph Product Suite. This comprehensive solution encompasses engineered nanoparticles, consumables, automation, instrumentation, and software, all designed to enable deep, unbiased proteomic analysis efficiently. Seer’s user-friendly Proteograph workflow positions itself as a crucial resource for laboratories eager to explore the proteome.
Frequently Asked Questions
What innovations did Seer present at HUPO 2024?
Seer showcased significant advancements in proteomics, particularly focusing on Alzheimer's research, population health, and novel blood sampling techniques.
Who presented the Alzheimer's study at HUPO 2024?
Harendra Guturu presented the study that explored the impact of genetic variants on Alzheimer's Disease using mass spectrometry proteogenomics.
What is the Proteograph Product Suite?
The Proteograph Product Suite is Seer's integrated solution that streamlines deep, unbiased proteomic analysis using proprietary technology and automation.
How many protein groups were identified in the population health study?
Over 8,100 protein groups were identified in the population-scale plasma proteomics study conducted with 1,600 plasma samples.
What is the potential application of Seer's DBS analysis?
The DBS analysis advances early biomarker discovery by enabling less invasive sampling and increasing detection capabilities of proteins from blood samples.
